Abstract
Autoimmune diseases represent a group of conditions where the immune system mistakenly attacks the body’s own cells. Biopharmaceuticals have emerged as a promising class of therapeutic agents for treating these diseases by targeting specific components of the immune system. This article discusses the formulation and design of biopharmaceuticals, including monoclonal antibodies, cytokine inhibitors, and other biologics, for the treatment of autoimmune disorders. The mechanisms of action, challenges in formulation, and regulatory considerations are explored. Additionally, the article highlights the advancements in personalized medicine, which aim to optimize biopharmaceutical therapies based on individual patient profiles.
References
Ahmad, N. R. (2025). Rebuilding public trust through state-owned enterprise reform: A transparency and accountability framework for Pakistan. Punjab Sahulat Bazaars Authority. https://doi.org/10.52152/6q2p9250
Ahmad, N. R. (2025). Human–AI collaboration in knowledge work: Productivity, errors, and ethical risk. https://doi.org/10.52152/6q2p9250

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Dr. Nida Imran (Author)